Relief Ultra rectal suppositories 12 pcs — Made in Germany — Free Delivery

In order to minimize systemic effects, the recommended dose should not be exceeded, unless otherwise recommended by a doctor.

Use during pregnancy and lactation. The safety of using the preparation Relif® Ultra (hydrocortisone acetate, zinc sulfate) during pregnancy has not been studied.

Modern data on the safety of the use of topical corticosteroids during pregnancy indicate that there is no connection between their use by the mother and the development of the cleft palate, premature birth and fetal death.

Modern data indicate that the use of strong / very strong topical GCS during pregnancy cannot be associated with placental insufficiency and low birth weight of the newborn. However, these are data from one large and small cohort studies. A large population-based cohort study (84,133 pregnant women from the database of general practice studies) revealed a significant association of fetal growth retardation with the use of strong / very strong topical corticosteroids in pregnant women, but not with weak / moderate strength topical corticosteroids. The relationship between the use of a pregnant woman with topical GCS of any strength with the development of the cleft palate, premature birth and fetal death has not been identified. Also, another cohort study conducted in Denmark did not reveal a causal relationship between the use of topical corticosteroids and the cleft palate.

It is not known whether the active ingredients of Relief® Ultra (hydrocortisone acetate, zinc sulfate) pass into breast milk. Trace amounts of endogenous hydrocortisone (cortisol) are excreted in breast milk. The amount of GCS in milk ranges from 0.2 to 32 ng / ml with a maximum average concentration (25.5 ng / ml), which is determined in colostrum at the end of pregnancy. The concentration of hydrocortisone in colostrum averages 7.5% of the plasma level.

There are no reports of exogenous hydrocortisone or cortisone excretion in breast milk. It is unlikely that these substances will have an adverse effect on a breastfed newborn. Prednisolone, a stronger GCS than hydrocortisone, is excreted in breast milk in minimal amounts and is considered compatible with breastfeeding.

During pregnancy and lactation, the preparation can be used if, in the opinion of the doctor, the benefit to the mother outweighs the potential risk to the fetus. The preparation in this group should not be widely used in pregnant women, especially in high doses or for a long time.

You should consult your doctor before using this medicine.

Studies on the effect of Relief® Ultra (hydrocortisone acetate, zinc sulfate) on human fertility have not been carried out.

The ability to influence the reaction rate when driving or operating other mechanisms. No data available.

Use with caution while treating with anticoagulants, hypoglycemic agents, barbiturates, diuretics, cardiac glycosides.

With simultaneous use with other GCS (both topical and oral), the likelihood of developing systemic effects may increase.

Concomitant use with CYP 3A inhibitors (including preparations containing cobicistat) may increase the risk of systemic side effects, including adrenal suppression. Simultaneous use should be avoided, except in cases where the benefits of using the preparation outweighs the risk of developing systemic effects of GCS, and it is necessary to monitor the patient's condition.

Long-term use in high doses enhances resorption and increases the risk of developing systemic effects of hydrocortisone, such as menstrual irregularities, increased blood pressure, delayed wound healing, muscle weakness, insomnia, increased blood glucose levels, hirsutism, glaucoma, etc.

If accidentally swallowed, gastrointestinal disorders (nausea, stomach pain) may occur.

At a temperature not higher than 25 ° C.